Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain

Background. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) decrease cardiovascular mortality and slow the progression of renal disease in non-transplant patients, but their impact on kidney transplant outcome has not been well established. Methods. Patients receiving a renal allograft in Spain in 1990, 1994, 1998 and 2002 were considered for the present study. Only adult (≥18 years) recipients of a single kidney transplant functioning at the end of the first year were considered. A total of 4842 patients with clinical data about ACEI/ARB therapy were included. Results. During the initial 2 years after transplant, ACEI/ARB were less frequently used in the 1990 and 1994 cohorts than in 1998 and 2002 (15.1%, 24.6%, 33.5% and 45.1%, respectively; P < 0.001). During the first year, a total of 1063 patients (22.8%) received ACEI/ARB treatment, and graft survival (50.0% for treated patients and 51.4% for untreated, P = ns), death-censored graft survival (60.6% versus 63.5%, P = ns) and patient survival (68.8% versus 66.6%, P = ns) were not different. During the initial 2 years, 1472 patients (31.4%) received treatment with ACEI/ARB, and graft survival tended to be higher in treated patients (54.4% and 50.9%, P = 0.063). Since there was an interaction between ACEI/ARB treatment and year of transplant, graft survival was analysed in each cohort. Cox regression analysis including the propensity score for ACEI/ARB treatment showed an association between ACEI/ARB treatment and graft survival in the 2002 cohort (relative risk 0.36 and 95% confidence interval 0.17–0.75, P = 0.007). Death-censored graft survival (63.8% versus 63.1%, P = ns) and patient survival (68.1% and 66.5%, P = ns) were not significantly different. Conclusions. The use of ACEI/ARB during the initial 2 years after transplantation was associated with a better graft survival, but this effect was only observed in the 2002 cohort.

[1]  M. Pirmohamed,et al.  Randomized Controlled Trial: Lisinopril Reduces Proteinuria, Ammonia, and Renal Polypeptide Tubular Catabolism in Patients With Chronic Allograft Nephropathy , 2010, Transplantation.

[2]  R. Townsend,et al.  Is there added value to adding ARB to ACE inhibitors in the management of CKD? , 2009, Journal of the American Society of Nephrology : JASN.

[3]  M. Zeier,et al.  No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. , 2006, Journal of the American Society of Nephrology : JASN.

[4]  G. Heinze,et al.  Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. , 2006, Journal of the American Society of Nephrology : JASN.

[5]  R. Rodger,et al.  Hypertension, antihypertensive agents and outcomes following renal transplantation , 2005, Clinical transplantation.

[6]  G. Borm,et al.  Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  B. Palmer.  Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. , 2004, The New England journal of medicine.

[8]  J. Zaltzman,et al.  The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  G. Knoll,et al.  The Burden of Chronic Kidney Disease in Renal Transplant Recipients , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  M. Ghoneim,et al.  Effect of Angiotensin II Receptor Blocker on Plasma Levels of TGF-β1 and Interstitial Fibrosis in Hypertensive Kidney Transplant Patients , 2003, American Journal of Nephrology.

[11]  V. D’Agati,et al.  Angiotensin converting enzyme inhibition in chronic allograft nephropathy , 2002, Transplantation.

[12]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[13]  F. Moreso,et al.  Prevention and management of late renal allograft dysfunction. , 2001, Journal of nephrology.

[14]  M. Sayegh,et al.  Chronic allograft dysfunction: mechanisms and new approaches to therapy. , 2000, Seminars in nephrology.

[15]  A. Richards,et al.  Blockade of the renin-angiotensin system. , 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[16]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1993 .

[17]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.

[18]  S. Hirematha,et al.  Renin Angiotensin System Blockade in Kidney Transplantation : A Systematic Review of the Evidence , 2007 .

[19]  M. Vivera,et al.  ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[20]  H. Parving.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. , 1994, The New England journal of medicine.